INTRODUCTION {#sec1-1}
============

It is estimated that 5-15% of mild-moderate pancreatitis and 20% of necrotizing pancreatitis are complicated by the development of pancreatic fluid collections (PFCs): pseudocysts (PPs) or walled-off necrosis (WON), respectively.\[[@ref1]\] The vast majority of acute PFCs resolve spontaneously and do not require any intervention. PFC drainage of mature collections with a definite wall is required when they rapidly increase in size, and/or become infected or symptomatic.\[[@ref1]\] Percutaneous and surgical drainage were the main treatment modalities for symptomatic PFCs before the introduction of endoscopic transmural pancreatic drainage, first described in 1989,\[[@ref2]\] with significant advantages in terms of morbidity and mortality.

The endoscopic approach is now most commonly performed under endoscopic ultrasound (EUS)-guidance since it increases safety visualizing vessels in the drainage pathway and technical success, by including non-bulging PFCs and those located in the tail of the pancreas.\[[@ref3]\] In the last couple of years, lumen-apposing metal stents (LAMS) have been preferred over plastic stents for management of PFCs and have shown several advantages over them. The bilateral double-walled anchoring flanges hold the gastric or duodenal wall in direct apposition to PFC on the newly formed anastomosis, thus preventing leakage and migration. The larger luminal diameter (10-15 mm) allows subsequent direct endoscopic debridement in case of WON, often required for effective control of infection. With the second-generation device, a further refinement of the stent delivery system has been developed. It incorporates an electrocautery tip, enabling a single device to be used, when previously multiple devices and steps were required.

Many systematic reviews and meta-analyses evaluating efficacy and safety of LAMS have been performed, but literature on the removal timing of this device is still scarce, with a lack of international consensus.

The recently published guidelines of the European Society of Gastrointestinal Endoscopy (ESGE)\[[@ref3]\] on acute necrotizing pancreatitis recommend to retrieve LAMS within 4 weeks, but the level of evidence is low.

In order to improve the state of knowledge on this issue, we analyzed all eligible articles reporting timing and complications of LAMS removal.

METHODS {#sec1-2}
=======

Study selection {#sec2-1}
---------------

We systematically analyzed Medline/Pubmed database in order to identify articles investigating LAMS placement for PFC drainage. The keywords used were: pancreatic fluid collection, pseudocyst, walled off necrosis, LAMS, Hot Axios, Axios, EUS guided drainage. The research resulted in identification of 45 publications; all the abstracts were initially screened for suitability. After exclusion of 27 studies, following the aforementioned criteria, a total of 18 publications were included in the review. Studies comparing different types of stents (self-expandable metal stents, plastic stents) and case reports were also included. There were no restrictions on the study dates and the last literature search was performed in October 2018.

Inclusion criteria {#sec2-2}
------------------

Studies reporting the timing of retrieval of LAMS placed for pancreatic fluid collection drainage in patients over the age of 18.

Exclusion criteria {#sec2-3}
------------------

Studies about LAMS not explicitly taking into consideration the removal timing, studies including only stents different than LAMS.

Outcome measures {#sec2-4}
----------------

These included efficacy of removal, complications such as the "buried stent syndrome", and immediate and delayed adverse events related to the stent retrieval.

Characteristics of included studies {#sec2-5}
-----------------------------------

Medline/Pubmed research resulted in the identification of 18 studies. After detailed examination of the full texts, 12 original studies, 2 case series, 2 case reports, 1 multi-institutional consensus and 1 evidence-based multidisciplinary guideline were considered eligible\[[@ref1][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19]\] for inclusion in our review. All articles cited in ESGE guidelines,\[[@ref3]\] in relation to removal timing, were included.\[[@ref4][@ref5]\]

Not all the selected studies indicated in details the LAMS used. When reported, the most frequent ones were the Axios and Hot Axios stents. Axios stent TM (Boston Scientific, Natick MA, USA) is a through-the-scope, large-diameter, fully covered self-expanding metal stent (FCSEMS) with bilateral double-walled anchoring flanges specifically designed to create an anastomosis, holding the PFC wall in direct apposition to the stomach or duodenal wall. The "Hot" version of this device includes an electrocautery at the tip of the delivery catheter, allowing direct access to the PFC without the need for multiple steps. The stents are 10 mm in length and available in two different lumen diameters (10 mm and 15 mm). Very recently, a 20 mm diameter stent has become commercially available as well.

RESULTS {#sec1-3}
=======

Description of included studies {#sec2-6}
-------------------------------

18 studies were considered eligible. Of these, 12 were original articles, out of which 5 compared the efficacy of LAMS with other types of stents (plastic or double-flanged metal stents).\[[@ref5][@ref6][@ref7][@ref8][@ref9]\] Among the original studies, 4 had a prospective\[[@ref4][@ref5][@ref10][@ref11]\] and 8 a retrospective design;\[[@ref6][@ref7][@ref8][@ref9][@ref12][@ref13][@ref14][@ref15]\] the other papers included a multi-institutional consensus on PFC drainage,\[[@ref1]\] the 2018 ESGE guidelines on acute necrotizing pancreatitis,\[[@ref3]\] 2 case reports\[[@ref16][@ref17]\] and 2 case series,\[[@ref18][@ref19]\] focusing on complications related to LAMS removal.

Patient and study characteristics {#sec2-7}
---------------------------------

Patient characteristics, types of lesions and study details are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Type of lesions, patient characteristics (treated with LAMS) and study details

  Author/Year                 PCF Type       PFC size mm (range)   Male/tot patients (%)   Type of Study
  --------------------------- -------------- --------------------- ----------------------- ----------------------------------
  Bekkali *et al*. 2017       WON            140 (110-170)         27/32 (84)              Original Article (retrospective)
  Walter *et al*. 2014        45 WON/15 PP   90 (40-200)           38/62 (61)              Original Article (prospective)
  Shah *et al*. 2015          WON            150 (90-230)          18/33 (54)              Original Article (prospective)
  Lang *et al*. 2018          9 WON/10 PP    104 (67-155)          10/19 (53)              Original Article (retrospective)
  Yoo *et al*. 2017           22 WON/3 PP    82 (60-170)           14/25 (56)              Original Article (retrospective)
  Law *et al*. 2018           WON            9 (8-10)              32/46 (70)              Original Article (retrospective)
  Adler *et al*. 2017         9 WON/4 PP     138 (60-159)          5/13 (38)               Original Article (retrospective)
  Gornals *et al*. 2013       WON            90 (70-150)           7/9 (78)                Original Article (prospective)
  Rinninella *et al*. 2015    52 WON/18 PP   100 (38-240)          22/70 (31)              Original Article (retrospective)
  Siddiqui *et al*. 2016      68 WON/12 PP   118 (48-290)          48/80 (60)              Original Article (retrospective)
  Bang *et al*. 2017          WON            \> 60 mm              Not Indicated           Original Article (prospective)
  Sahar *et al*. 2017         WON            153 (93-230)          17/25 (68)              Original Article (retrospective)
  Fabbri *et al*. 2015        PFC            Not Indicated         1 (100)                 Case Report
  Zhu *et al*. 2018           PP             150 x 150             1 (100)                 Case Report
  Itoi *et al*. 2011          PP             98 (55-200)           12/15 (80)              Case Series
  Seerden *et al*. 2016       PP             Not Indicated         2/2 (100)               Case Series
  Arvanitakis *et al*. 2018   PFC            \-                    \-                      Guideline
  Guo *et al*. 2017           PFC            \-                    \-                      Multi-institutional consensus

Of the 12 original studies, 8 evaluated drainage of both PP and WON,\[[@ref4][@ref7][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] and 4 included only patients with WON.\[[@ref5][@ref6][@ref8][@ref9]\] The 2 case reports involved one patient with PP\[[@ref17]\] and one with PFC (no further specification),\[[@ref16]\] respectively, while the 2 case series included patients with PPs.\[[@ref18][@ref19]\]

Axios stent TM (Boston Scientific, MA, USA) was used in 7 of the original studies,\[[@ref4][@ref7][@ref9][@ref11][@ref13][@ref15]\] in 1 case series\[[@ref18]\] and in 1 case report.\[[@ref16]\] The other case series\[[@ref19]\] and 3 of the 12 original studies\[[@ref5][@ref6][@ref14]\] reported the use of the version with an incorporated electrocautery-enhanced delivery system, the Hot Axios. Both Axios and Hot Axios were used in 1 original study.\[[@ref8]\] The type of LAMS was not described in 1 case report and in 1 original study.\[[@ref12][@ref17]\] ESGE guideline\[[@ref3]\] refers to LAMS in general as well.

Outcome measures {#sec2-8}
----------------

Type of stent, removal timing and adverse events associated are summarized in [Table 2](#T2){ref-type="table"}.

###### 

Type of stent, removal timing and adverse events

  Author/Year                 Stent Type            Removal timing in weeks                             Adverse Events (*n*)
  --------------------------- --------------------- --------------------------------------------------- --------------------------------------
  Bekkali *et al*. 2017       Hot Axios             6-13                                                Buried Stent (1)
  Walter *et al*. 2014        Axios                 1-20                                                Tissue Ingrowht
  Shah *et al*. 2015          Axios                 3-9                                                 None
  Lang *et al*. 2018          Axios                 At discretion of endoscopist after PFC resolution   None
  Yoo *et al*. 2017           LAMS                  At discretion of endoscopist after PFC resolution   None
  Law *et al*. 2018           Axios and Hot Axios   4-12                                                None
  Adler *et al*. 2017         Axios                 4-16                                                None
  Gornals *et al*. 2013       Axios                 6-12                                                None
  Rinninella *et al*. 2015    Hot Axios             4-16                                                Buried Stent (1)
  Itoi *et al*. 2011          Axios                 1-12                                                None
  Siddiqui *et al*. 2016      Axios                 4-16                                                None
  Bang *et al*. 2017          Hot Axios             5-6                                                 Buried Stent (2)
  Sahar *et al*. 2017         Axios                 Not indicated                                       None
  Fabbri *et al*. 2015        Axios                 4                                                   Buried Stent (1)
  Zhu *et al*. 2018           LAMS                  20                                                  Buried Stent (1)
  Seerden *et al*. 2016       Hot Axios             12                                                  Buried Stent (1)
  Arvanitakis *et al*. 2018   LAMS                  4                                                   See Walter *et al*. and Bang *et al*
  Guo *et al*. 2017           LAMS                  3-12                                                Not Indicated

### Timing of LAMS removal {#sec3-1}

In a retrospective study by Bekkali *et al*.,\[[@ref6]\] mean removal time was 9 weeks; at the time of publication of the study 2 LAMS were yet to be removed. In 6 studies\[[@ref5][@ref8][@ref11][@ref13][@ref14][@ref19]\] reported mean time of LAMS removal ranged between 8-12 weeks.

The removal timing was not precisely indicated in 3 studies.\[[@ref7][@ref9][@ref12]\] The study by Lang *et al*.\[[@ref7]\] reports stent removal at the discretion of the endoscopist, after resolution of the PFC was observed. Sahar *et al*.\[[@ref9]\] wrote that "every LAMS has to be removed once placed" and reports the US FDA indications of stent dwell time approved for 60 days. However, after these considerations, analyzing the adverse events, they reported the removal of a LAMS 73 days after release, due to the development of a large colonic fistula from erosion of the distal flange. It is unclear if they followed the FDA indications or they were guided by clinical/radiological findings. They also reported that LAMS were replaced with 2 double pigtail plastic stents in 67% of cases, in order to provide long-term drainage in disconnected pancreatic duct syndrome, not explaining the timing of the procedure. In the study by Yoo *et al*.,\[[@ref12]\] stent removal was undertaken after complete decompression of the PFC without persistence of fluid component.

### Adverse events and LAMS removal technique {#sec3-2}

Buried stent syndrome has been reported in 3 studies\[[@ref5][@ref6][@ref14]\] and in 1 case report.\[[@ref16]\] Fabbri *et al*.\[[@ref16]\] encountered a complete buried stent recognizable by the presence of an orifice in the middle of a small bulge of gastric mucosa. They cannulated and dilated with a balloon and, after identification of the extremity embedded LAMS in the gastric wall, they removed it with a rat-tooth forceps, without adverse events. In the study by Bang *et al*.\[[@ref5]\] 2 cases of buried stents were reported. In one, the stent was retrieved after transmural tract dilation using a large diameter biopsy forceps. In the other patient, stent retrieval resulted in massive hemorrhage requiring radiology-guided coil embolization. In the study by Bekkali *et al*.\[[@ref6]\] (with a mean removal time of 9 weeks) one patient, lost to follow-up for 26 weeks, had a buried stent in the gastric wall. Further attempts at removal were postponed because of pregnancy.

Four studies\[[@ref4][@ref10][@ref17][@ref19]\] reported mucosal overgrowth. They were resolved endoscopically, without any further trouble in removing the stent.

Zhu *et al*.\[[@ref17]\] found severe tissue adhesion after 5 months and removed LAMS wires one by one with forceps. In another case report,\[[@ref19]\] the gastroscopy scheduled at three months showed tissue overgrowth at the gastric flange of the LAMS which made it impossible to remove with a rat-tooth forceps or snare. Forced argon plasma coagulation (APC), needle-knife incision, and dilation of the stent were necessary to remove it.

In the study by Yoo *et al*.,\[[@ref12]\] all stents were successfully removed using a snare after PFC resolution without significant adverse events. There was a spontaneous extrusion of one LAMS into the enteral lumen after resolution of the WON.

We found no association between type/dimension of the PFC and removal complications or between removal timing and removal complications. Mucosal overgrowth or buried stent was not associated with longer indwell of the stent, since they appeared even after 4 weeks of placement.

DISCUSSION {#sec1-4}
==========

Although we are well aware that the articles we evaluated are heterogeneous, we included all the papers reporting LAMS removal timing. This is because these stents are relatively new, their reported clinical experience is still scarce if compared to other types of stents, and the number of patients analyzed in this setting is still low.

The recently published ESGE guidelines\[[@ref3]\] on acute necrotizing pancreatitis strongly recommended, in case of PFC drainage, a LAMS removal timing not exceeding 4 weeks. However, the cited studies on which the recommendation is based suffer of the same aforementioned limitations, hence the low quality of evidence. We decided to include this paper in order to underline the paucity of data in support of the statement.

In the study by Walter *et al*.,\[[@ref4]\] the median time of removal in 47 patients was 32 days, in line with the suggested 4 weeks, but the differences in the group were huge: from 2-178 days; furthermore, the authors described a 23% of noted tissue growth in the stent, with uneventful removal, but with no specifications regarding the time of stent indwelling in the patient and the complication.

The largest study is the retrospective multi-centric analysis by Rinninella *et al*.,\[[@ref14]\] which evaluated 93 patients with PFCs underwent drainage using the Hot Axios stent, with clinical resolution in 86 patients and successful stent removal in 83. In 2 patients with advanced malignant disease, the stent was left in place, while in one, lost at follow-up for more than 4 months, the stent was buried within the gastric wall due to overgrowth of the surrounding gastric mucosa. To avoid adverse events, the endoscopist decided to avoid stent removal.

Siddiqui *et al*.\[[@ref15]\] performed a large multi-center, retrospective study on 82 patients with symptomatic PFC who underwent EUS-guided drainage by using the Axios stent. All stents were endoscopically successfully removed by using a snare or grasping forceps, after a median duration of 2 months (range 1-3 months), after PFC resolution. No significant clinical adverse events were described after stent retrieval.

In the study by Yoo *et al*.,\[[@ref12]\] stent removal was performed after complete resolution of the PFC. Since the follow-up period was 7-8 months, it remains a moot point whether the stent could be left *in situ* for such a long time?

We encountered the issue of the "buried stent" in a patient who underwent LAMS placement for a WON and then was lost at follow-up for 5 months. Although clinically silent and under monitoring, the stent is still in place after 2 failed attempts of removal. In this case, the stent was buried in the gastric mucosa, but with the help of a Needle Knife and using the APC device, we succeeded in completely freeing the proximal flange of the stent in the stomach. However, the distal flange remained buried in the retroperitoneal tissue. The policy of our center is to retrieve the LAMS within 4 weeks, as suggested by ESGE guidelines,\[[@ref3]\] even though in at least 2 patients, with a radiological documented resolution of the WON at 3^rd^ week, the 4-week scheduled removal was particularly complicated because of initial overgrowth of gastric mucosa on the proximal edge of the stent. A similar condition is described in the studies by Fabbri *et al*.\[[@ref16]\] and Rinninella *et al*.\[[@ref14]\]

Another case of "buried stent" is reported in the study by Bang *et al*.,\[[@ref5]\] comparing PFC drainage with LAMS (12) vs plastic stents (9). In the LAMS group, stent retrieval was scheduled after 5 or 6 weeks post-index procedure, and was successfully performed in 10 patients. In the latter two, the LAMS were found buried under the gastric mucosa and removal was not free from adverse events. Although in this paper, data on timing makes the group of patients more homogeneous, the number is still too low to formulate any high-evidence recommendations.

The prospective analysis of Shah *et al*.\[[@ref10]\] evaluated the outcomes of lumen-apposing, covered, self-expanding metal stent (LACSEMS) placement in 30 patients with PFCs. Except for 1 patient, with a second plastic drainage, among the remaining 29 patients, stents remained implanted for 31 days in 20 patients (+/- 9.9 days) and for 67 days in 9 patients (+/-10.8 days). Despite that mucosal overgrowth and hyper plastic tissue reaction were described in 2 cases, in all 29 patients, the stents were removed successfully.

CONCLUSION {#sec1-5}
==========

The scarce available data tend to support the 4-week timing for LAMS removal, as recommended by ESGE guidelines.\[[@ref3]\] Nevertheless, there is still a need for large prospective cohort studies, in order to prove a relationship between removal timing, outcome, and adverse events related to LAMS.
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